ArticleNature communications2026
Arginine methyltransferase PRMT1 equipoises trophoblast development to prevent early pregnancy loss.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic Reprogramming at the Maternal-Fetal Interface: Insights from Decidual Stromal Cells and Trophoblasts in Healthy Pregnancy Versus Recurrent Pregnancy Loss.International journal of molecular sciences · 2026Review
Corrections and comments
- Update of
Authors and funding
9 authors.
Funding
Abstract
Idiopathic recurrent pregnancy loss (RPL) affects 1-2% of human pregnancies, yet the underlying molecular causes are poorly understood. Here we identify defective Protein Arginine Methyltransferase 1 (PRMT1) function in trophoblast progenitors as a cause of early pregnancy failure. PRMT1 is highly conserved in mammalian trophoblast progenitors, and conditional deletion of Prmt1 in mouse trophoblast progenitors arrests placental and embryonic development, resulting in lethality at ~E7.5. In humans, a subset of idiopathic RPL cases exhibits loss of PRMT1 in cytotrophoblast progenitors (CTBs). Human trophoblast stem cells (hTSCs) derived from these RPL placentas, together with PRMT1-depleted hTSCs, demonstrate an essential role for PRMT1 in maintaining trophoblast progenitor self-renewal. RNA-seq and CUT&RUN analyses reveal that PRMT1 promotes expression of stem-state regulators, including TEAD4 and MYBL2, through enrichment of histone H4 arginine 3 asymmetric dimethylation (H4R3Me2a) at their chromatin loci. PRMT1 is required for extravillous trophoblast (EVT) development, whereas its loss promotes spontaneous syncytiotrophoblast (STB) differentiation. Together, these findings identify the PRMT1-H4R3Me2a axis as a conserved epigenetic regulator of trophoblast development and pregnancy maintenance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.